Background: In China, gastric cancer (GC) is one of the most common malignant tumors. This study aimed to explore the relationship of rs2297810, rs4646491 and rs2297809 polymorphisms of CYP4B1 with susceptibility to GC in the Chinese Han population. Methods: A case-control study including 707 GC cases and 707 normal controls was conducted. Three single nucleotide polymorphisms (SNPs) were genotyped by Agena MassARRAY system. Logistic regression analysis was utilized to assess the effects of SNPs on GC risk. Furthermore, multifactor dimensionality reduction (MDR) approach was used to analyze the SNP-SNP interactions. Results: No significant relationships were found between rs2297810 and rs2297809 and GC risk under all genetic models. For rs4646491, people with TC genotype had a 1.40-fold higher risk of GC than those with CC genotype (OR = 1.40; 95% CI = 1.13–1.74; p = 0.002), and people with TT-TC genotype had a 1.30-fold higher risk of GC than those with CC genotype (OR = 1.30; 95% CI = 1.06–1.61; p = 0.014). Stratification results showed that GC risk in people carrying TC genotype was higher than that in people with CC genotype, males (OR = 1.36; 95% CI = 1.06–1.75; p = 0.015), non-smokers (OR = 1.52; 95% CI = 1.11–2.07; p = 0.009) and non-drinkers (OR = 1.50; 95% CI = 1.10–2.04; p = 0.010). Additionally, the study also revealed that GC risk in people carrying TT-TC genotype was higher than that in people with CC genotype, males (OR = 1.29; 95% CI = 1.01–1.64; p = 0.040), non-smokers (OR = 1.40; 95% CI = 1.04–1.89; p = 0.027) and non-drinkers (OR = 1.39; 95% CI = 1.03–1.87; p = 0.030). Conclusion: This study firstly found that CYP4B1-rs4646491 was significantly correlated with GC risk, and it might be a risk factor for GC.
BackgroundNeoadjuvant chemoimmunotherapy (NCIO) is more effective than neoadjuvant immunotherapy alone for pathological response in non-small cell lung cancer (NSCLC) patients, but the processes for determining patient suitability for its implementation are not clear. We aimed to identify the most relevant factors and build a convenient model to select NSCLC patients who would benefit most from NCIO.Methods We retrospectively collected the clinical data of patients with locally advanced NSCLC who received NCIO followed by surgery at our institution between January 2019 and July 2022.ResultsA total of 101 eligible stage IIB-IIIC NSCLC patients were included. After NCIO, all patients successfully underwent surgical resection. A total of 46.53% (47/101) of patients achieved pathological complete response (pCR), and 70.30% (71/101) achieved major pathologic response (MPR). Tumor regression rate (adjusted odds ratio OR = 12.33), PD-L1 expression (adjusted odds ratio (OR) = 9.66), pembrolizumab/nab-paclitaxel–based regimens (adjusted OR = 4.92), and comorbidities (adjusted OR = 0.16) were independently associated with pCR rate (all P < 0.05). Tumor regression rate (adjusted OR = 8.45), PD-L1 expression (adjusted OR = 5.35), and presence of squamous cell carcinoma (adjusted OR = 7.02) were independently associated with MPR rate (all P < 0.05). We established and validated an easy-to-use clinical model to predict pCR (with an area under the curve [AUC] of 0.848) and MPR (with an AUC of 0.847). Of note, the present study showed that CD4+ T-cell count/rate and total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) levels in the peripheral blood of pre-NCIO patients were also significantly correlated with pathological response in univariate analyses.ConclusionsThe tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel–based regimens, presence of squamous cell carcinoma, and comorbidities were the main influential factors for incidence of pCR/MPR in patients with stage IIB-IIIC NSCLC in the present study. Through predictive models, we can predict who will benefit most from NCIO prior to the emergence of clinical outcomes in locally advanced NSCLC.
Neoadjuvant chemoimmunotherapy (NCIO) is a new and effective treatment for cancer, but it is not clear for which patients it is suitable. In our previous study, we did not find any correlation between baseline peripheral blood routine tests and the efficacy of NCIO in non-small cell lung cancer (NSCLC). In this study, we aimed to investigate whether changes in these routine tests after treatment were associated with efficacy of NCIO in NSCLC. We retrospectively collected clinical data of patients with NSCLC who received NCIO followed by surgery from January 2019 to July 2022 at our institution.We included 95 patients with stage IIB-IIIC NSCLC. At week 6 after two cycles of NCIO, the absolute or changed values (or rates) in peripheral blood routine tests were associated with pathological complete response (pCR)/major pathological response (MPR). Changed rate of white blood cell (WBC) count [adjusted odds ratio (OR) = 5.24, P = 0.003] and changed rate of monocyte count (adjusted OR = 4.67, P = 0.017), and absolute prothrombin time ratio at week 6 (adjusted OR = 8.27, P = 0.012) were independently associated with pCR. Changed value of WBC count (adjusted OR = 4.23, P = 0.048), absolute basophil count at week 6 (adjusted OR = 5.05, P = 0.023), changed rate of monocyte count (adjusted OR = 4.37, P = 0.034) and absolute aspartate aminotransferase (AST) level at week 6 (adjusted OR = 15.78, P < 0.001) were independently associated with MPR. Based on the five independent factors, we established easy-to-use clinical models to predict pCR and MPR with area under the curve (AUC) values of 0.785 and 0.881, respectively. Of note, we found change' rate of monocyte count, absolute basophil count, AST and blood magnesium levels at week 6 may be promising biomarkers for NCIO in NSCLC. These peripheral blood routine tests at week 6 after NCIO were better predicted the efficacy of NCIO in NSCLC than at baseline. It is feasible to establish clinical predictive models through these parameters, and their predictive values were consistent with the pathological criteria of pCR and MPR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.